Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidence

被引:0
|
作者
Eva Esteban Cardeñosa
Pascual Bolufer Gilabert
Inmaculada de Juan Jiménez
Sarai Palanca Suela
Eva Barragán González
Virginia González Anguix
Enrique Lerma Alejos
Isabel Chirivella González
Ángel Segura Huerta
Carmen Guillén Ponce
Eduardo Martínez de Dueñas
Dolores Cuevas Cuerda
Dolores Salas Trejo
机构
[1] University Hospital La Fe,Laboratory of Molecular Biology. Service of Clinical Analysis
[2] Hospital Clínico Universitario,Unit of Genetic Counselling in Cancer
[3] Hospital Universitario La Fe,Unit of Genetic Counselling in Cancer
[4] Hospital General de Elche,Unit of Genetic Counselling in Cancer
[5] Consorcio Hospital Provincial,Unit of Genetic Counselling in Cancer
[6] Health Agency of Valencia,Service of Protocolization and Assistance Integration, Healthcare General Directorate
[7] Consellería de Sanitat,Cancer Plan Office, Department of Public Health
来源
Familial Cancer | 2010年 / 9卷
关键词
Breast cancer; Ovarian cancer; /; mutations; Family selection criteria; Tumor incidence;
D O I
暂无
中图分类号
学科分类号
摘要
The aim of the present study is to analyze the relationship of the incidence of mutations in the two major genes BRCA1 and BRCA2 conferring risk of breast cancer (BC) and ovarian cancer (OC) with the cancer burden in families and with the presence and age of onset of BC/OC. We included 704 index patients (IP) and 668 family members of the IP who tested positive for BRCA1/BRCA2 who were studied in the Program of Genetic Counselling in Cancer of the Valencia Community (Spain). We found 129 IPs with deleterious mutations (18.3%), 59 in BRCA1 and 70 in BRCA2, detecting 396 mutations in this kindred. The incidence of mutations and their distribution between BRCA1 and BRCA2 showed a significantly uneven incidence among the family groups (P < 0.001). We found 179 tumors in the 396 mutation carriers (45%) and detected only 11 cancers among the 272 non-mutation carriers (P < 0.001). No differences in the tumor prevalence or the age of onset of cancer between the genes among the mutation carriers were found. The mutation carriers showed a 50% probability of having BC/OC at a median age of 49 years (95% CI 46–52 years) and 78% at the age of 70 years (95% CI: 71–85%). In conclusion the family burden of BC and OC is strongly associated with the incidence of BRCAs mutations and could foretell which of the two BRCAs genes is more likely to have mutations. Mutation carriers have a 50% risk of having BC/OC by the age of 50 years.
引用
收藏
页码:291 / 295
页数:4
相关论文
共 50 条
  • [1] Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidence
    Esteban Cardenosa, Eva
    Bolufer Gilabert, Pascual
    de Juan Jimenez, Inmaculada
    Palanca Suela, Sarai
    Barragan Gonzalez, Eva
    Gonzalez Anguix, Virginia
    Lerma Alejos, Enrique
    Chirivella Gonzalez, Isabel
    Segura Huerta, Angel
    Guillen Ponce, Carmen
    Martinez de Duenas, Eduardo
    Cuevas Cuerda, Dolores
    Salas Trejo, Dolores
    FAMILIAL CANCER, 2010, 9 (03) : 291 - 295
  • [2] Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
    Birkbak, Nicolai Juul
    Kochupurakkal, Bose
    Izarzugaza, Jose M. G.
    Eklund, Aron C.
    Li, Yang
    Liu, Joyce
    Szallasi, Zoltan
    Matulonis, Ursula A.
    Richardson, Andrea L.
    Iglehart, J. Dirk
    Wang, Zhigang C.
    PLOS ONE, 2013, 8 (11):
  • [3] High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer
    Smirnova, T. Yu.
    Pospekhova, N. I.
    Lyubchenko, L. N.
    Tjulandin, S. A.
    Gar'kavtseva, R. F.
    Ginter, E. K.
    Karpukhin, A. V.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2007, 144 (01) : 83 - 85
  • [4] High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer
    T. Yu. Smirnova
    N. I. Pospekhova
    L. N. Lyubchenko
    S. A. Tjulandin
    R. F. Gar’kavtseva
    E. K. Ginter
    A. V. Karpukhin
    Bulletin of Experimental Biology and Medicine, 2007, 144 : 83 - 85
  • [5] BRCA1 and BRCA2 Mutations in Ovarian Cancer
    Buerkle, Bernd
    Tempfer, Clemens
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 359 - 359
  • [6] BRCA1 and BRCA2 Mutations and Breast Cancer
    Narod, Steven A.
    Salmena, Leonardo
    DISCOVERY MEDICINE, 2011, 12 (66) : 445 - 453
  • [7] A family with three germline mutations in BRCA1 and BRCA2
    Liede, A
    Metcalfe, K
    Offit, K
    Brown, K
    Miller, S
    Narod, SA
    Moslehi, R
    CLINICAL GENETICS, 1998, 54 (03) : 215 - 218
  • [8] Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations
    Metcalfe, Kelly
    Lubinski, Jan
    Lynch, Henry T.
    Ghadirian, Parviz
    Foulkes, William D.
    Kim-Sing, Charmaine
    Neuhausen, Susan
    Tung, Nadine
    Rosen, Barry
    Gronwald, Jacek
    Ainsworth, Peter
    Sweet, Kevin
    Eisen, Andrea
    Sun, Ping
    Narod, Steven A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (24): : 1874 - 1878
  • [9] Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients
    Choi, DH
    Lee, NH
    Bale, AE
    Carter, D
    Haffty, BG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) : 1638 - 1645
  • [10] Incidence of germline BRCA1 and BRCA2 mutations among Filipinos
    Que, Frances Victoria Fajardo
    Ang, Daphne
    Andal, Jose Jasper
    Madrid, Manuelito
    Lo, Raymundo
    Imasa, Marcelo
    Enriquez, Ma. Luisa
    Tria, Francisco
    Cabral, Loraine Kay
    Dimalibot, Rosil
    Li, Rubi Khaw
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)